Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02595866
Title Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Alabama at Birmingham Cancer Center Birmingham Alabama 35233 United States Details
Zuckerberg San Francisco General Hospital San Francisco California 94110 United States Details
UCSF Medical Center-Parnassus San Francisco California 94143 United States Details
Yale University New Haven Connecticut 06520 United States Details
Louisiana State University Health Science Center New Orleans Louisiana 70112 United States Details
University of Maryland/Greenebaum Cancer Center Baltimore Maryland 21201 United States Details
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland 21287 United States Details
National Institutes of Health Clinical Center Bethesda Maryland 20892 United States Details
Roswell Park Cancer Institute Buffalo New York 14263 United States Details
Laura and Isaac Perlmutter Cancer Center at NYU Langone New York New York 10016 United States Details
Mount Sinai Hospital New York New York 10029 United States Details
FHCC South Lake Union Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field